{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:40:58Z","timestamp":1782787258545,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1F1A1076839"],"award-info":[{"award-number":["2020R1F1A1076839"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1F1A1076839"],"award-info":[{"award-number":["NRF-2020R1F1A1076839"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1I1A306686511"],"award-info":[{"award-number":["NRF-2020R1I1A306686511"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006107","name":"Gil Medical Center, Gachon University","doi-asserted-by":"publisher","award":["FRD2019-08"],"award-info":[{"award-number":["FRD2019-08"]}],"id":[{"id":"10.13039\/501100006107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006107","name":"Gil Medical Center, Gachon University","doi-asserted-by":"publisher","award":["FRD2019-14."],"award-info":[{"award-number":["FRD2019-14."]}],"id":[{"id":"10.13039\/501100006107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Increased prevalence of antibiotic resistance to Helicobacter pylori (H. pylori) infection worldwide has driven the search for a new therapeutic candidate. Recently, sitafloxacin, a novel 4-quinolone agent, has emerged as a new therapeutic option for H. pylori eradication, in Japan. However, data on its efficacy for H. pylori eradication in Korea are limited. Therefore, we aimed to investigate the therapeutic potential of sitafloxacin as a first-line treatment for patients with Helicobacter infection through gastric tissue culture-based studies. Materials and Methods: We prospectively enrolled treatment-na\u00efve patients with H. pylori infection who visited the Gil Medical Center between March 2015 and March 2018. After obtaining written informed consent from patients, a total of 121 H. pylori strains were collected. We tested the susceptibility of these strains to sitafloxacin, and other antibiotics for Helicobacter eradication, including clarithromycin (CLR), metronidazole (MTZ), amoxicillin (AMX), tetracycline (TET), levofloxacin (LEV), and ciprofloxacin (CIP) using the agar dilution technique. The minimum inhibitory concentration (MIC) of these antibiotics against H. pylori strains were determined. Results: None of the H. pylori strains obtained were resistant to sitafloxacin (MIC &gt; 1, n = 0), while other conventional eradication drugs including CLR, MTZ, AMX, and TET showed 24.8% (n = 30), 30.6% (n = 37), 5.0% (n = 6), and 0.8% (n = 1) resistance, respectively. Compared to the resistance rates of other quinolones (LEV [36.4%, n = 44] and CIP [37.2%, n = 45]), sitafloxacin showed the best antibiotic performance against Helicobacter strains (0%, n = 0). Furthermore, sitafloxacin also inhibited the growth of 14 H. pylori strains (12.4%), which were resistant to both of clarithromycin, and metronidazole, and 27 strains (22.3%) with multidrug resistance. Conclusions: Sitafloxacin might be a new promising candidate for Helicobacter eradication where antibiotic resistance for Helicobacter is an emerging medical burden, such as in Korea.<\/jats:p>","DOI":"10.3390\/antibiotics10101242","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T09:33:02Z","timestamp":1634117582000},"page":"1242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-6752","authenticated-orcid":false,"given":"Youn I","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Min","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0869-7661","authenticated-orcid":false,"given":"Jun-Won","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Oh","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang An","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8477-6823","authenticated-orcid":false,"given":"Yoon Jae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-473X","authenticated-orcid":false,"given":"Jung Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Mi","family":"Lee","sequence":"additional","affiliation":[{"name":"Asan Medical Center, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Jeong","sequence":"additional","affiliation":[{"name":"Asan Medical Center, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul 05505, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Kyun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00535-019-01639-w","article-title":"Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication","volume":"55","author":"Take","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics","volume":"157","author":"Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","first-page":"1411","article-title":"Prevalence and Pattern of Antibiotic Resistant Strains of Helicobacter pylori Infection in ASEAN","volume":"19","author":"Vilaichone","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/17512433.2019.1654858","article-title":"Multidrug resistance in Helicobacter pylori: Current state and future directions","volume":"12","author":"Boyanova","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1089\/mdr.2020.0088","article-title":"An Updated Systematic Review and Meta-Analysis on the Helicobacter pylori Antibiotic Resistance in Iran (2010\u20132020)","volume":"26","author":"Khademi","year":"2020","journal-title":"Microb. Drug Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1128\/AAC.01552-08","article-title":"Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations","volume":"53","author":"Murakami","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jgh.12442","article-title":"Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan","volume":"29","author":"Furuta","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/11207380-000000000-00000","article-title":"Sitafloxacin","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4291\/wjgp.v5.i4.392","article-title":"Treatment of Helicobacter pylori infection: Past, present and future","volume":"5","author":"Papastergiou","year":"2014","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"The global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9351801","DOI":"10.1155\/2019\/9351801","article-title":"Rifabutin and furazolidone could be the candidates of the rescue regimen for antibiotic-resistant H. pylori in Korea","volume":"2019","author":"Choi","year":"2019","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Humphries, R.M., Kircher, S., Ferrell, A., Krause, K.M., Malherbe, R., Hsiung, A., and Burnham, C.-A.D. (2018). The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group. J. Clin. Microbiol., 56.","DOI":"10.1128\/JCM.00437-18"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2011.12.002","article-title":"Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan","volume":"39","author":"Hirata","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/AAC.00049-09","article-title":"Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation","volume":"53","author":"Suzuki","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.05941-11","article-title":"Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies","volume":"56","author":"Matsuzaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2169\/internalmedicine.53.1677","article-title":"Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin","volume":"53","author":"Furuta","year":"2014","journal-title":"Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/apt.13280","article-title":"High Helicobacter pylori cure rate with sitafloxacin-based triple therapy","volume":"42","author":"Sugimoto","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3748\/wjg.v26.i15.1733","article-title":"Update on quinolone-containing rescue therapies for Helicobacter pylori infection","volume":"26","author":"Mori","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","article-title":"Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure","volume":"23","author":"Gisbert","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","article-title":"Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis","volume":"101","author":"Saad","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1086\/510074","article-title":"The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection","volume":"44","author":"Carothers","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5662\/wjm.v5.i3.164","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review","volume":"5","author":"Ghotaslou","year":"2015","journal-title":"World J. Methodol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rangel, A.A.T., Otero, W., Galvis, A.A., Poutou-Pi\u00f1ales, R.A., Rimbara, E., and Graham, D.Y. (2016). Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogot\u00e1-Colombia (2009-2014). PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160007"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1523-5378.2006.00415.x","article-title":"Primary Levofloxacin Resistance and gyrA\/B Mutations Among Helicobacter pylori in Japan","volume":"11","author":"Miyachi","year":"2006","journal-title":"Helicobacter"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3748\/wjg.v24.i40.4548","article-title":"Second-line rescue treatment of Helicobacter pylori infection: Where are we now?","volume":"24","author":"Lin","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e12660","DOI":"10.1111\/hel.12660","article-title":"Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018","volume":"24","author":"Lee","year":"2019","journal-title":"Helicobacter"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13756-019-0482-x","article-title":"Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics","volume":"8","author":"Miftahussurur","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Miftahussurur, M., Cruz, M., Doohan, D., Subsomwong, P., Abreu, J.A.J., Hosking, C., Waskito, L.A., and Yamaoka, Y. (2019). Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213868"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/46.2.283","article-title":"Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin\/dalfopristin and new quinolones","volume":"46","author":"Martin","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00535-012-0731-8","article-title":"Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan","volume":"48","author":"Murakami","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1159\/000501610","article-title":"10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy","volume":"101","author":"Mori","year":"2019","journal-title":"Digestion"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/1040841X.2017.1418285","article-title":"Resistance mechanisms of Helicobacter pylori and its dual target precise therapy","volume":"44","author":"Gong","year":"2018","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fmolb.2014.00019","article-title":"Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing","volume":"1","author":"Nishizawa","year":"2014","journal-title":"Front. Mol. Biosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/2050640616688995","article-title":"Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxa-cin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients","volume":"5","author":"Mori","year":"2017","journal-title":"United European Gastroenterol. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.3748\/wjg.v24.i29.3302","article-title":"Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis","volume":"24","author":"An","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1128\/AAC.44.4.1102-1107.2000","article-title":"In Vitro Activities of Sitafloxacin (DU-6859a) and Six Other Fluoroquinolones against 8,796 Clinical Bacterial Isolates","volume":"44","author":"Milatovic","year":"2000","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/10\/1242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:12:37Z","timestamp":1760166757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/10\/1242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["antibiotics10101242"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10101242","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}